Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.3K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.3K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.8K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.8K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.8K
Blood Transfusion01:15

Blood Transfusion

2.9K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.9K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.0K
Overview
86.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced DNA capture in silicon nitride nanopores <i>via</i> localized photothermal convection.

Nanoscale·2026
Same author

Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.

International journal of hematology·2025
Same author

Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia.

American journal of hematology·2025
Same author

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Blood advances·2025
Same author

High-dose romiplostim for donor-type aplasia.

Annals of hematology·2025
Same author

Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.

International journal of hematology·2025
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in management of systemic AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K

[Acquired aplastic anemia].

Hirohito Yamazaki1

  • 1Division of Transfusion Medicine, Kanazawa University Hospital.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|March 4, 2016
PubMed
Summary
This summary is machine-generated.

Idiopathic aplastic anemia (AA) is an autoimmune T-cell disorder. Research explores new treatments like eltrombopag and advances in bone marrow transplantation for AA patients.

More Related Videos

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

10.1K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.4K

Related Experiment Videos

Last Updated: Mar 24, 2026

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K
Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

10.1K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.4K

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • Idiopathic aplastic anemia (AA) is an autoimmune disease primarily mediated by T cells.
  • Evidence suggests T-cell involvement through glycosylphosphatidylinositol-anchored protein-deficient cells and HLA allele-lacking leukocytes.
  • Somatic mutations in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) genes are found in a third of AA patients.

Purpose of the Study:

  • To review current treatment strategies for aplastic anemia.
  • To evaluate the efficacy of eltrombopag in refractory and newly diagnosed AA.
  • To discuss advancements and challenges in allogeneic bone marrow transplantation for AA.

Main Methods:

  • Review of current literature on aplastic anemia treatments.
  • Analysis of eltrombopag efficacy in combination therapies and transplantation.
  • Examination of fludarabine-based preconditioning regimens and their outcomes.

Main Results:

  • Eltrombopag shows efficacy in refractory AA and newly diagnosed AA when combined with ATG and cyclosporine.
  • Allogeneic bone marrow transplantation with reduced-intensity conditioning and eltrombopag improves outcomes.
  • Fludarabine-based regimens reduce transplant-related mortality but introduce challenges like mixed chimerism and graft failure.

Conclusions:

  • Eltrombopag is a valuable therapeutic option for aplastic anemia.
  • Advances in bone marrow transplantation offer improved outcomes but require management of new complications.
  • Ongoing research focuses on optimizing preconditioning regimens to prevent graft-versus-host disease (GVHD).